The MHRA's decision was based on the totality of preclinical; clinical; and chemistry, manufacturing, and controls data reviewed by the agency. This includes two pivotal, ongoing phase III clinical trials including Prevent-19. The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. The vaccine is stored at 2° to 8° Celsius and has a current assigned shelf life in Great Britain of nine months.

Novavax previously announced an agreement with the U.K. Vaccines Taskforce for up to 60 million doses of Novavax's COVID-19 vaccine. Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Novavax submits EUA request to FDA for COVID-19 vaccine
Novavax submitted a request to the U.S Food and Drug Administration (FDA) for emergency use authorization (EUA) for NVX-CoV2373, its protein-based COVID-19...

Novavax receives CMA from European Commission
Novavax announced that the European Commission has granted the company a conditional marketing authorization (CMA) for its Nuvaxovid COVID-19 vaccine...

Novavax completes submission of COVID vaccine candidate to WHO
Novavax has completed its rolling submission to the World Health Organization (WHO) for emergency use listing of NVX-CoV2373, its COVID-19 vaccine candidate.

Novavax submits COVID vaccine candidate to TGA
Novavax completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate in Australia.

Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...